Miller EM, et al. – Intraperitoneal (IV/IP) chemotherapy was compared with intravenous (IV) chemotherapy in order to define their utilization and clinical results in a racially and ethnically diverse population with optimally debulked advanced stage epithelial ovarian cancer. Half of the patients received IV/IP chemotherapy in the racially diverse urban patients. This resulted in improved overall survival compared to IV chemotherapy alone. These findings encouraged to examine barriers to use of IV/IP chemotherapy.

Methods

• After IRB approval, clinicians ascertained all patients diagnosed with epithelial ovarian cancer that underwent primary cytoreductive surgery at the institution from 2005 to 2016.
• The National Social Security Death Index verified the death.
• In the IV/IP cohort, patients who received at least one IV/IP cycle were analyzed.
• They performed Kaplan-Meier and Cox proportional hazards models.

Results

• This study recognized 96 patients with advanced stage optimally cytoreduced epithelial ovarian cancer (median follow up 33 months).
• IV/IP and IV chemotherapy were administered to 51% and 49% of patients, respectively.
• It was reported that 27%, 22%, and 39% of patients were of white, black, and other race.
• Data demonstrated an association between IV/IP chemotherapy and longer OS (log rank < 0.002) versus IV chemotherapy only.
• In addition, IV/IP chemotherapy versus IV chemotherapy alone was associated with a lower risk of death (HR = 0.31, 95% CI 0.16–0.62, P < 0.001).
• According to the investigation, the median overall survival for the IV/IP and IV groups was 76 months (95% CI 62 - not estimated) and 38 months (95% CI 30–55), respectively.
• A trend toward higher risk of death was noticed for patients who completed fewer than 6 cycles of IV/IP chemotherapy compared to women who completed 6 IV/IP cycles (HR = 3.2, 95% CI 0.98–9.27 (P = 0.05).
• There were no differences in patient or tumor characteristics between these two groups of patients.